U.K. Panel Says: Continue DES Use, But Limit Price Premium Over Bare Metal
This article was originally published in The Gray Sheet
Executive Summary
The United Kingdom's National Institute of Health and Clinical Excellence has retreated from its August 2007 recommendation that the country's National Health Service stop paying for drug-eluting stents after being bombarded with criticism from interventional cardiologists and stent manufacturers